

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 1 of 2

ATTY. DOCKET NO.
33659-US-PCT
APPLICATION NO.
Not yet known
APPLICANT
ROGER MICHAEL LANE
FILING DATE

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						
AL						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	NO
AM	2005/051297	6/9/05	WO			<input type="checkbox"/>	<input type="checkbox"/>
AN						<input type="checkbox"/>	<input type="checkbox"/>
AO						<input type="checkbox"/>	<input type="checkbox"/>
AP						<input type="checkbox"/>	<input type="checkbox"/>
AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	Nagy, Christa F. et al., "Concurrent administration of donepezil HC1 and sertraline HC1 in healthy volunteers: assessment of pharmacokinetic changes and safety following single and multiple oral doses". British Journal of Clinical Pharmacology, vol. 58, no. Suppl. 1, pp. 25-33, (2004)
AS	Roman, G.C., "Vascular dementia: Changing the paradigm". Current Opinion in Psychiatry 2003 United Kingdom, vol. 16, no. 6, pp. 635-641, (2003).
AT	Am. J. Psychiatry, vol. 154, pp. 562-565, (1997).

EXAMINER /Gregg Polansky/ DATE CONSIDERED 03/18/2008

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.P./

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
33659-US-PCT
APPLICATION NO.
Not yet known
APPLICANT
ROGER MICHAEL LANE
FILING DATE

Group

EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

DA	Roman, G C, et al., "Subcortical ischaemic vascular dementia", Lancet Neurology, Lancet Publishing Group, London, GB, vol. 1, no. 7, pp.426-436, (2002).
DD	Bentue, Ferrer D, et al. "Clinically Significant Drug Interactions with Cholinesterase Inhibitors: A Guide for Neurologists", CNS Drugs, New Zealand, vol. 17, no. 13, pp. 947-960, (2003).
DC	Cheline Yi, Freedland Ke, Gamey RM. "How safe are serotonin reuptake inhibitors for depression in patients with coronary heart disease? Jant, 102(1):54-5", Ann Journal Of Medicine, vol. 1, no. 102, pp. 54-5, (1997).
DD	Krepp G, et al., "Diagnostic steps in possible Alzheimer dementia before starting with new therapeutics", Fortschritte Der Neurologie Psychiatrie, Germany, vol. 68, no. 6, pp. 257-261, (2000).
DE	Farlow M R, "Clinical Pharmacokinetics of Galantamine", Clinical Pharmacokinetics, New Zealand, vol. 42, no. 15, pp. 1383-1392, (2003).
DF	
DG	
DH	
DI	
DJ	
DK	
DL	
DM	
DN	

EXAMINER

/Gregg Polansky/

DATE CONSIDERED

03/18/2008

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.P./